Gabexate and nafamostat share 4 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.167 means 17% of the combined target set is bound by both compounds. The IDF-weighted score of 0.170 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Gabexate and nafamostat have in common?
Gabexate and nafamostat share 4 molecular targets with a Jaccard similarity of 17%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Gabexate and nafamostat be combined?
Gabexate and nafamostat share 4 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Gabexate or nafamostat?
In the BiohacksAI corpus: Gabexate has 300 PubMed-indexed studies, nafamostat has 0 studies.